Design,synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors |
| |
| Institution: | 1. Computational Laboratory, Medicinal Chemistry Division, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan 333 031, India;2. Medicinal Chemistry Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan 333 031, India;1. Department of Chemistry, Section for Chemical Biology and Nanobioscience, Faculty of Science, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark;2. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark;3. CNRS, UMR 6296, ICCF, BP 80026, 63171 Aubière, France;4. Clermont Université, Université Blaise Pascal, Institut de Chimie de Clermont-Ferrand, BP 10448, 63000 Clermont-Ferrand, France;1. Inorganic and Physical Chemistry Division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 007, India;2. Laboratory of X-ray Crystallography, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 007, India;3. Medicinal Chemistry and Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad 500 007, India;1. Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya nab., Saint Petersburg 199034, Russia;2. Center for X-ray Diffraction Studies, Saint Petersburg State University, Saint Petersburg, Russia;1. Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, ?wirki i Wigury 101, 02-089 Warszawa, Poland;2. Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 5a Pawińskiego Street, 02-106 Warsaw, Poland |
| |
| Abstract: | The identification of a series of sulfonyl-amino-acetamides as BACE-1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease is reported. The derivatives were designed based on the docking simulation study, synthesized and assessed for BACE-1 inhibition in vitro. The designed ligands revealed desired binding interactions with the catalytic aspartate dyad and occupance of S1 and S2′ active site regions. These in silico results correlated well with in vitro activity. Out of 33 compounds synthesized, 12 compounds showed significant inhibition at 10 μM concentration. The most active compound 2.17S had IC50 of 7.90 μM against BACE-1, which was concomitant with results of in silico docking study. |
| |
| Keywords: | Alzheimer’s disease BACE-1 inhibitors Sulfonyl-amino-acetamide Docking simulation FRET assay |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
